The trademark LIPICORE was filed by TRx Biosciences Limited, a corporation established under the laws of the United Kingdom of Great Britain and Northern Ireland (the "Applicant"). The application was published for oppositions on July 22, 2021, and received undefined oppositions.
Opposition Proceedings
There are undefined Oppositions claimed against trademark.
The first opposition filed on October 24, 2021 by Upjohn Manufacturing Ireland Unlimited Company on Likelihood of confusion. the opponent was represented by Koch, Manuela and its proceedings were handled in English The second opposition filed on October 24, 2021 by OmniVision GmbH on Likelihood of confusion. the opponent was represented by LORENZ SEIDLER GOSSEL RECHTSANWÄLTE PATENTANWÄLTE PARTNERSCHAFT MBB and its proceedings were handled in English
The application was filed in English, and English was also language of all opposition proceedings (Spanish was selected as the second language).
The Opposition with reference B 003157219 was refused according to Article 8(1)(b) EUTMR with decision issued on September 26, 2024 by the EUIPO.
Goods And Services
The mark was filed in class 5 with following description of goods:
Non-aqueous, hydrophobic fat matrix used in a drug delivery system for the manufacture of oral pharmaceutical, veterinary and medical preparations
Drug delivery systems containing a non-aqueous, hydrophobic fat matrix used in formulating oral pharmaceutical, veterinary and medical products
None of the aforesaid goods being used for/or in connection with the treatment of hypercholesterol.
The mark was filed in class 42 with following description of goods:
Research services relating to formulation development of non-aqueous, hydrophobic fat matrix used for the manufacture of oral pharmaceutical, veterinary and medical products
Research services relating to use of drug delivery systems containing a non-aqueous, hydrophobic fat matrix use in formulating of oral pharmaceutical, veterinary and medical preparations
Development of non-aqueous, hydrophobic fat matrix used in a drug delivery system for the manufacture of oral pharmaceutical, veterinary and medical preparations
Development of a drug delivery system containing a non- aqueous, hydrophobic fat matrix used in formulating oral pharmaceutical, veterinary and medical products
None of the aforesaid services being used for/or in connection with the treatment of hypercholesterol.